Hepatology and Metabolic Liver Disease
Clinical research is centered on metabolic dysfunction-associated steatohepatitis, with attention to liver inflammation and fibrosis in patients with verified non-alcoholic steatohepatitis.
- Steatohepatitis
- Liver histology
- Fibrosis staging
Research activity in this area reflects an interest in monitoring structural liver changes associated with chronic metabolic liver injury.
Endocrine and Metabolic Disorders
The sponsor’s trial portfolio includes investigation of metabolic pathways relevant to fatty liver disease, with focus on conditions linked to insulin resistance and systemic metabolic dysfunction.
- Metabolic dysfunction
- Fatty liver disease
- Glucose metabolism
This places the sponsor within clinical research addressing liver disease in the context of broader metabolic abnormalities.
Cardiometabolic Therapeutics
Interest extends to the use of empagliflozin in patients with NASH, linking liver outcomes with therapies commonly associated with cardiometabolic disease management.
- SGLT2 inhibition
- Cardiometabolic disease
- Therapeutic liver remodeling
The funded research examines liver-related effects within a treatment context that intersects metabolic and cardiovascular care.
